Sell Colgate Palmolive; target of Rs 823: Motilal Oswal

13145 Investors following Colgate. Share this News with them.

0

Like this story, share it with millions of investors on M3

Sell Colgate Palmolive; target of Rs 823: Motilal Oswal

Motilal Oswal is bearish on Colgate Palmolive and has recommended sell rating on the stock with a target of Rs 823 in its January 24, 2012 research report.

Post your opinion here

 

0

Tweet

Share on Tumblr

RELATED NEWS Sell Ranbaxy Laboratories; target Rs 355: PINC Research Buy IRB Infrastructure; target of Rs 221: KRChoksey Buy IL&FS Transportation; target Rs 224: PINC Research ALSO READ See previous views by Motilal Oswal See what other Experts & Brokerages are saying about Colgate See messages about Colgate Colgate BSE | NSE 01/06/12 Are Mutual Funds betting on Colgate?

Motilal Oswal is bearish on Colgate Palmolive and has recommended sell rating on the stock with a target of Rs 823 in its January 24, 2012 research report.

"Colgate Palmolive (CLGT) posted 74% YoY growth in 3QFY12 PAT to INR1.16b v/s our estimate of INR1.01b. Toothpaste volume growth was robust at 15%. Market share during the period December 2010-November 2011 was 52.5%. Overall volume growth was 13% for the second consecutive quarter. EBITDA margin expanded 550bp YoY as OHM (Oral Health Month) got pushed from 3Q to 4Q, resulting in 550bp decline in ad spend. 520bp lower tax rate also boosted profitability."

"CLGT is setting up a new toothpaste facility at Sanand in Gujarat, for which it has paid lease charges of INR426m for land. We estimate the capital cost at INR2b spread over FY12 and FY13. The company has sufficient capacity to maintain its growth trajectory till the new unit comes on stream. Competitive intensity in oral care is a major challenge for CLGT in the medium term; we note that it has been losing toothbrush market share to P&G's Oral-B in recent months. CLGT is also facing intense competition from Glaxo's Sensodyne in the super premium segment. Media reports indicate that P&G has started pilot testing of toothpaste in India, which could result in its product being launched in FY13 itself. We expect sales growth and profit margins to take a hit once P&G launches its toothpaste in India."

"We are raising our earnings estimates by 1%, which captures the net impact of lower interest income due to capex and tax rate 100-150bp lower than the earlier estimate. We expect 12.5% PAT CAGR over FY11-13, led largely by volume growth in oral care. The stock trades at 31x FY12E and 26x FY13E EPS. Current valuations build in structural positives and are at 25% premium to the 5-year average P/E multiple. Maintain Sell," says Motilal Oswal research report.

FIIs holding more than 30% in Indian cos

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

To read the full report click on the attachment